Telomir Pharmaceuticals (TELO) Competitors $1.83 0.00 (0.00%) Closing price 08/5/2025 04:00 PM EasternExtended Trading$1.80 -0.03 (-1.86%) As of 04:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TELO vs. CRDF, EDIT, REPL, FENC, BTMD, DRUG, ACIU, TRDA, PRQR, and LRMRShould you be buying Telomir Pharmaceuticals stock or one of its competitors? The main competitors of Telomir Pharmaceuticals include Cardiff Oncology (CRDF), Editas Medicine (EDIT), Replimune Group (REPL), Adherex Technologies (FENC), biote (BTMD), Bright Minds Biosciences (DRUG), AC Immune (ACIU), Entrada Therapeutics (TRDA), ProQR Therapeutics (PRQR), and Larimar Therapeutics (LRMR). These companies are all part of the "pharmaceutical products" industry. Telomir Pharmaceuticals vs. Its Competitors Cardiff Oncology Editas Medicine Replimune Group Adherex Technologies biote Bright Minds Biosciences AC Immune Entrada Therapeutics ProQR Therapeutics Larimar Therapeutics Cardiff Oncology (NASDAQ:CRDF) and Telomir Pharmaceuticals (NASDAQ:TELO) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, media sentiment, earnings and dividends. Is CRDF or TELO more profitable? Telomir Pharmaceuticals has a net margin of 0.00% compared to Cardiff Oncology's net margin of -9,344.14%. Cardiff Oncology's return on equity of -77.94% beat Telomir Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Cardiff Oncology-9,344.14% -77.94% -63.65% Telomir Pharmaceuticals N/A -2,009.40%-1,009.72% Which has stronger earnings and valuation, CRDF or TELO? Telomir Pharmaceuticals has lower revenue, but higher earnings than Cardiff Oncology. Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCardiff Oncology$680K251.44-$45.43M-$0.87-2.95Telomir PharmaceuticalsN/AN/A-$16.53M-$0.42-4.36 Which has more volatility & risk, CRDF or TELO? Cardiff Oncology has a beta of 1.54, suggesting that its stock price is 54% more volatile than the S&P 500. Comparatively, Telomir Pharmaceuticals has a beta of -0.67, suggesting that its stock price is 167% less volatile than the S&P 500. Do insiders & institutionals hold more shares of CRDF or TELO? 16.3% of Cardiff Oncology shares are held by institutional investors. 7.7% of Cardiff Oncology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Do analysts prefer CRDF or TELO? Cardiff Oncology currently has a consensus price target of $11.70, suggesting a potential upside of 355.25%. Telomir Pharmaceuticals has a consensus price target of $15.00, suggesting a potential upside of 719.67%. Given Telomir Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Telomir Pharmaceuticals is more favorable than Cardiff Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cardiff Oncology 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83Telomir Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Does the media favor CRDF or TELO? In the previous week, Cardiff Oncology had 20 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 20 mentions for Cardiff Oncology and 0 mentions for Telomir Pharmaceuticals. Cardiff Oncology's average media sentiment score of 0.54 beat Telomir Pharmaceuticals' score of 0.00 indicating that Cardiff Oncology is being referred to more favorably in the media. Company Overall Sentiment Cardiff Oncology Positive Telomir Pharmaceuticals Neutral SummaryCardiff Oncology beats Telomir Pharmaceuticals on 10 of the 16 factors compared between the two stocks. Get Telomir Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TELO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TELO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TELO vs. The Competition Export to ExcelMetricTelomir PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$54.47M$2.53B$5.59B$9.53BDividend YieldN/A1.77%4.73%4.14%P/E Ratio-4.369.1628.9123.88Price / SalesN/A717.24448.7998.82Price / CashN/A159.4135.6858.35Price / Book91.505.078.165.60Net Income-$16.53M$31.61M$3.25B$265.26M7 Day Performance-6.63%-0.38%1.15%-0.14%1 Month Performance55.08%5.79%8.25%6.08%1 Year Performance-46.80%3.58%29.18%24.22% Telomir Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TELOTelomir Pharmaceuticals2.9096 of 5 stars$1.83flat$15.00+719.7%-46.5%$54.47MN/A-4.361Upcoming EarningsCRDFCardiff Oncology1.8021 of 5 stars$3.31-11.3%$11.70+253.5%+24.5%$248.14M$680K-3.6020Positive NewsHigh Trading VolumeEDITEditas Medicine4.1181 of 5 stars$2.59-12.5%$4.70+81.5%-45.0%$247.79M$32.31M-0.85230News CoverageREPLReplimune Group4.3664 of 5 stars$3.75+18.3%$7.67+104.4%-35.0%$246.65MN/A-1.22210Trending NewsHigh Trading VolumeFENCAdherex Technologies2.3471 of 5 stars$8.54-1.4%$13.00+52.2%+42.6%$240.17M$47.54M-16.7510News CoverageUpcoming EarningsBTMDbiote2.9966 of 5 stars$4.55+4.1%$8.00+75.8%-38.9%$239.08M$199.38M7.46194High Trading VolumeDRUGBright Minds Biosciences1.6667 of 5 stars$34.82+2.8%$83.25+139.1%+3,178.7%$238.51MN/A-96.72N/AUpcoming EarningsACIUAC Immune2.003 of 5 stars$2.35-0.8%$12.00+410.6%-29.8%$237.97M$31.02M-4.05140News CoveragePositive NewsTRDAEntrada Therapeutics3.2403 of 5 stars$6.29+1.0%$25.67+308.1%-59.7%$236.45M$172.22M7.77110Positive NewsUpcoming EarningsPRQRProQR Therapeutics1.9999 of 5 stars$2.19-2.2%$8.00+265.3%+11.6%$235.68M$20.46M-6.26180LRMRLarimar Therapeutics2.9541 of 5 stars$3.53-3.0%$18.50+424.1%-49.6%$233.06MN/A-2.3730News CoverageInsider TradeGap Up Related Companies and Tools Related Companies Cardiff Oncology Alternatives Editas Medicine Alternatives Replimune Group Alternatives Adherex Technologies Alternatives biote Alternatives Bright Minds Biosciences Alternatives AC Immune Alternatives Entrada Therapeutics Alternatives ProQR Therapeutics Alternatives Larimar Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TELO) was last updated on 8/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored[Warning] Buffett Indicator hits new All-Time-HighWarren Buffett has leaned on one key indicator for decades—and it just hit an all-time high. That’s not bullis...Golden Portfolio | SponsoredStrange twist to Bitcoin’s rallyThe #1 crypto to buy today Better than Bitcoin? (top crypto for less than $1) Over the past 15 years, B...Stansberry Research | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Telomir Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Telomir Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
